Review articleWhat do we know about the reduction of Pt(IV) pro-drugs?

Add time:08/30/2019    Source:sciencedirect.com

Platinum(IV) pro-drugs are an important class of molecules that might improve the pharmacological properties of the platinum(II) anticancer agents that are currently used in the clinic. Their axial ligands that are detached during cellular activation by reductive elimination can be used to confer favorable pharmacological properties to the complexes allowing for potentially lower toxicity and improved efficacy. This manuscript describes the various approaches taken to design and prepare Pt(IV) complexes that will be effective anticancer agents. We review the working hypotheses guiding the researchers in the field while pointing out some more recent results that contradict some of the accepted paradigms in the hope of triggering some rethinking of the existing working hypotheses.

We also recommend Trading Suppliers and Manufacturers of Dihydroxy Oxaliplatin-Pt(IV) (cas 111321-67-6). Pls Click Website Link as below: cas 111321-67-6 suppliers

Prev:Novel platinum(IV) complexes conjugated with a wogonin derivative as multi-targeted anticancer agents
Next:A theranostic prodrug delivery system based on Pt(IV) conjugated nano-graphene oxide with synergistic effect to enhance the therapeutic efficacy of Pt drug)